Skip to main content
Premium Trial:

Request an Annual Quote

PharmaDiagnostics Raises $3.5M in Private Financing

NEW YORK (GenomeWeb News) – PharmaDiagnostics, a Brussels, Belgium-based screening technologies firm, today announced that it has raised €2.5 million ($3.5 million) from its initial investors.

The company, which was founded in 2007, is developing a label-free screening technology that does not require specialized hardware. Its localized surface plasmon resonance technology is applicable to a range of assays for small molecule and antibody screening and characterization, the firm said. PharmaDiagnostics also claims that its technology enables label-free screening to be applied in high-throughput applications for the first time.

The lead investor in the round was Capital-E, an Antwerp, Belgium-based venture fund. Other investors in the round included Vinnof, the PhD Partnership, and Allegro Investment Fund. The firm noted that this round of financing is not yet closed, and it is in talks with potential additional investors.

PharmaDiagnostics intends to use the cash infusion to commercialize existing assays and further develop its technology for additional applications. It also said that it expects to conclude at least one customer deal in the fourth quarter of this year.

"PharmaDiagnostics has developed a unique and elegant new approach to label-free screening, enabling high-throughput and sensitive assays without the need for expensive, specialist equipment," said Marc Wachsmuth, partner at Capital-E. "The new funding will allow the management team to exploit this significant competitive advantage while developing further and marketing its technology."

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.